EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa : correlating clinical outcomes with hollow-fibre model input

María M Montero iD, Almudena Fernández-Muñoz, Sandra Domene-Ochoa, Silvia Castañeda, Inmaculada López-Montesinos, Sara Cortes-Lara, Sonia Luque iD, Maria Asunción Colomar, Xavier Mulet, Carla López-Causapé iD, Luisa Sorlí iD, Eduardo Padilla und 2 weitere

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkaf464 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von María M Montero und 13 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Service, Hospital del Mar. Infectious Pathology and Antimicrobials Research Group (IPAR), Hospital del Mar Research Institute (IM…. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, beta-Lactamases, Pseudomonas Infections, Anti-Bacterial Agents. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Economía y Competitividad of Spain, CIBER of Infectious Diseases, Institute of Health Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Infections caused by XDR Pseudomonas aeruginosa significantly limit treatment options. Although ceftolozane/tazobactam and ceftazidime/avibactam have emerged as promising alternatives, increasing resistance has been reported. This study describes three critically ill patients with ventilator-associated pneumonia caused by OXA-producing XDR P. aeruginosa that developed resistance to both agents during therapy.

Methods

Antibiotic exposure and resistance were monitored clinically and in a hollow-fibre infection model (HFIM) to evaluate different ceftazidime/avibactam and ceftolozane/tazobactam regimens. Drug concentrations, bacterial burden and resistant mutants were assessed. Whole-genome sequencing and resistance profiling were performed on both clinical and HFIM-derived isolates.

Results

Initial patient isolates were susceptible to both antibiotics. One belonged to ST179 (OXA-10 producer), while two were ST235 (OXA-2 or OXA-2 + OXA-10 producers). Resistance emerged during therapy in all cases. In the HFIM, continuous infusion of ceftolozane/tazobactam plus meropenem achieved bacterial eradication for ST179 within 8 h. For ST235 isolates, high-exposure ceftazidime/avibactam regimens (4-h or continuous infusion) achieved bacterial eradication and prevented regrowth. In contrast, low-exposure 2-h infusions allowed bacterial rebound and resistance selection. Mechanisms of resistance were similar across clinical and HFIM isolates, involving overexpression or structural modification of OXA enzymes, except in one ST235 HFIM derived-isolate, in which resistance development was caused by an AmpC Ω-loop mutation. Pharmacokinetic validation confirmed accurate drug exposure in the model.

Conclusions

These findings underscore the importance of optimized dosing strategies, particularly high-concentration and prolonged infusions, in eradicating and preventing resistance development in OXA-producing P. aeruginosa infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosabeta-LactamasesPseudomonas InfectionsAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialPneumonia, Ventilator-AssociatedHumansCeftazidimeAzabicyclo CompoundsCephalosporinsTazobactamMicrobial Sensitivity TestsMaleWhole Genome SequencingDrug CombinationsMiddle AgedFemaleAgedTreatment Outcomebeta-Lactamase Inhibitors

Substanzen

beta-LactamasesAnti-Bacterial AgentsCeftazidimeAzabicyclo CompoundsCephalosporinsTazobactamavibactam, ceftazidime drug combinationceftolozane, tazobactam drug combinationDrug Combinationsbeta-Lactamase Inhibitors

Autor:innen und Institutionen

  • Infectious Diseases Service, Hospital del Mar. Infectious Pathology and Antimicrobials Research Group (IPAR), Hospital del Mar Research Institute (IMIM), Barcelona, Spain.
  • Department of Medicine and Life Sciences (MELIS), Universitat Pompeu Fabra, Barcelona, Spain.
  • CIBER of Infectious Diseases (CIBERINFEC CB21/13/00002 and CB21/13/00099), Institute of Health Carlos III, Madrid, Spain.
  • Servicio de Microbiología y Unidad de Investigación, Hospital Son Espases, IdISBa, Palma de Mallorca, Spain.
  • Pharmacy Service, Hospital del Mar, Barcelona, Spain.
  • Medicina Intensiva, Hospital Son Espases, IdISBa, Palma de Mallorca, Spain.

ORCID-Profile: María M Montero, Sonia Luque, Carla López-Causapé, Luisa Sorlí

Förderung

  • Ministerio de Economía y Competitividad of Spain
  • CIBER of Infectious Diseases
  • Institute of Health Carlos III
  • European Union

Zitieren

APA

Montero, M. M., Fernández-Muñoz, A., Domene-Ochoa, S., Castañeda, S., López-Montesinos, I., Cortes-Lara, S., Luque, S., Colomar, M. A., Mulet, X., López-Causapé, C., Sorlí, L., Padilla, E., Horcajada, J. P., & Oliver, A. (2026). Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa : correlating clinical outcomes with hollow-fibre model input. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf464

Vancouver

Montero MM, Fernández-Muñoz A, Domene-Ochoa S, Castañeda S, López-Montesinos I, Cortes-Lara S, et al. Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa : correlating clinical outcomes with hollow-fibre model input. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf464

BibTeX
@article{Montero2026,
  author = {Montero, María M and Fernández-Muñoz, Almudena and Domene-Ochoa, Sandra and Castañeda, Silvia and López-Montesinos, Inmaculada and Cortes-Lara, Sara and Luque, Sonia and Colomar, Maria Asunción and Mulet, Xavier and López-Causapé, Carla and Sorlí, Luisa and Padilla, Eduardo and Horcajada, Juan P and Oliver, Antonio},
  title = {Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa : correlating clinical outcomes with hollow-fibre model input},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkaf464}
}
Kostenlos starten →